Abstract
BackgroundAdalimumab (ADA) is indicated for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Peripheral arthritis, enthesitis, and dactylitis are important features in patients (pts) suffering from spondyloarthritis (SpA)....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
